



Dr. Tamar Grossman is the CEO and co-founder of La Jolla Labs, a biotechnology company focused on advancing RNA-based therapeutics to address rare and complex diseases. With a career spanning over two decades, she has developed extensive expertise in RNA therapeutics, gene therapy, and drug delivery modalities, including siRNA, ASO, mRNA, saRNA, and gene editing. Previously, Dr. Grossman served as the Vice President and Global Head of RNA, Gene Therapy, and Delivery at Johnson & Johnson, where she led global teams in delivering RNA-based, gene therapy and ADC development candidates across therapeutic areas. Prior to her role at Johnson & Johnson, she was the Head of Rare Diseases at Arcturus Therapeutics, where she developed RNA therapeutics for rare and common disease. Earlier in her career, she held leadership positions at Ionis Pharmaceuticals, including Director of Translational Medicine, where she advanced antisense oligonucleotide programs from concept to clinical development. Dr. Grossman earned her PhD in Biochemistry from Tel-Aviv University and completed her postdoctoral training at UCSD. Under her leadership, La Jolla Labs has transitioned from a technology-driven company to an RNA therapeutics-focused organization, leveraging AI and machine learning to accelerate drug discovery and address unmet medical needs